@chump24042266 @paulsperry_ Not good, as I take Enbrel for RA. Rheumatologist often cites studies to me showing there’s no increased risk such as this one: https://t.co/fdtDZj01AL But who can we trust at this point?
@Kh_Saidani @DCharabaty @stevenbollipo @drkeithsiau @IBD_Afzali @Omkolsoumyahoo1 Start with budesonide and vedolizumab, and try to make it to 2 years with non-systemic Rx if possible. Population-level data in Denmark suggest that anti-TNF use after 2 years
RT @ezzatali64: Anti-tumour necrosis factor-α therapy and recurrent or new primary can... https://t.co/mJREzeuf7s @MondayNightIBD @DCharaba…
Anti-tumour necrosis factor-α therapy and recurrent or new primary can... https://t.co/mJREzeuf7s @MondayNightIBD @DCharabaty
RT @JZapatierGI: Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rh…
RT @MaiaKayalMD: Important data that anti-TNF therapy doesn’t increase risk of recurrent cancer!
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study - The Lancet Gastroent ht
RT @KrugCleveland: Excellent and much needed work! Anti TNF therapy does not increase of risk of recurrence or new cancer in patients with…
RT @JLPerezCalle: Important evidence
RT @MaiaKayalMD: Important data that anti-TNF therapy doesn’t increase risk of recurrent cancer!
RT @MaiaKayalMD: Important data that anti-TNF therapy doesn’t increase risk of recurrent cancer!
¡Información muy valiosa! @sepdigestiva @DigValdecilla @EIIValdecilla
RT @JLPerezCalle: Important evidence
RT @JLPerezCalle: Important evidence
Important evidence
A new piece of data reassuring the use of anti-TNF in patients with history of cancer. https://t.co/ehaN6vhq60
Important data that anti-TNF therapy doesn’t increase risk of recurrent cancer!
Excellent and much needed work! Anti TNF therapy does not increase of risk of recurrence or new cancer in patients with prior cancer history. By @AkbarWaljee @ibddoctor
Great info on an important topic to providers and #ibd patients alike! This really helps to support #shareddecisionmaking on what can feel like a difficult decision.
Anti-TNF therapy does not increase the risk of recurrent or new cancer in patients with prior cancer. (#IBD, #RA, #PsO). This is what we have thought from inference and now have good evidence to support. Nice work by @AkbarWaljee @ibddoctor #tinejess htt
RT @guthealthmd: Anti-tumour necrosis factor-α therapy and recurrent or new primary can... https://t.co/sE7yNzwGh3
RT @guthealthmd: Anti-tumour necrosis factor-α therapy and recurrent or new primary can... https://t.co/sE7yNzwGh3
Very important topic that comes up often enough Good to know that we can help those living with #IBD
Anti-tumour necrosis factor-α therapy and recurrent or new primary can... https://t.co/sE7yNzwGh3
@DCharabaty @AngusWorthing @MondayNightIBD @IBD_Afzali @ibdgijami @FITWITMD @UmaMahadevanIBD @SunandaKaneMD @MRegueiroMD @IBD_FloMD @P_DeepakIBDMD @EdwardLoftus2 @EdBarnesMD Why not switch to aTNF? Most recent collective data suggest no increase in de novo
@AngusWorthing @MondayNightIBD @DCharabaty Here a nice paper on the topic, anti-TNFα therapy was not associated with recurr or new 1ry ca develop in pts with previous ca. Timing of anti-TNFα after an initial cancer dx did not influence recurrent or new pri
RT @LancetGastroHep: New Online: Use of anti-TNFα therapy for #inflammatoryboweldisease, #rheumatoidarthritis, or #psoriasis is not associa…
元論文はこちら: Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study https://t.co/d0p
RT @Reumaclinic: Anti-TNF-α therapy and recurrent or new primary cancers in pts with IBD, RA or psoriasis & previous cancer 👉🏻Use of anti-T…
RT @Antonio28774221: Timing of anti-TNFα therapy after an initial cancer diagnosis did not influence recurrent or new primary cancer develo…
RT @LancetGastroHep: New Online: Use of anti-TNFα therapy for #inflammatoryboweldisease, #rheumatoidarthritis, or #psoriasis is not associa…
RT @LancetGastroHep: New Online: Use of anti-TNFα therapy for #inflammatoryboweldisease, #rheumatoidarthritis, or #psoriasis is not associa…
RT @LancetGastroHep: New Online: Use of anti-TNFα therapy for #inflammatoryboweldisease, #rheumatoidarthritis, or #psoriasis is not associa…
RT @MerayoDr: 👇🏻💈👇🏻💈👇🏻 Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel dise…
RT @MerayoDr: 👇🏻💈👇🏻💈👇🏻 Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel dise…
RT @MerayoDr: 👇🏻💈👇🏻💈👇🏻 Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel dise…
RT @Carlosguillenas: Parece que terminamos el año con una buena noticia para los pacientes usuarios de aTNF. https://t.co/QJUstYLtdA @ConAr…
RT @yasuaki_hasebe: 最近Denmarkから似た研究がちょうど出ていました。 こちらは過去に癌の既往があるIBDを含む自己免疫疾患の患者さんに対してTNFαを使った場合、新たな癌の発生、あるいは既存の癌の再発の増加は見られなかったという結果です。 https…
最近Denmarkから似た研究がちょうど出ていました。 こちらは過去に癌の既往があるIBDを含む自己免疫疾患の患者さんに対してTNFαを使った場合、新たな癌の発生、あるいは既存の癌の再発の増加は見られなかったという結果です。 https://t.co/sNDB3yMsDq
RT @Carlosguillenas: Parece que terminamos el año con una buena noticia para los pacientes usuarios de aTNF. https://t.co/QJUstYLtdA @ConAr…
RT @MerayoDr: 👇🏻💈👇🏻💈👇🏻 Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel dise…
RT @Carlosguillenas: Parece que terminamos el año con una buena noticia para los pacientes usuarios de aTNF. https://t.co/QJUstYLtdA @ConAr…
RT @Carlosguillenas: Parece que terminamos el año con una buena noticia para los pacientes usuarios de aTNF. https://t.co/QJUstYLtdA @ConAr…
RT @MerayoDr: 👇🏻💈👇🏻💈👇🏻 Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel dise…
👇🏻💈👇🏻💈👇🏻 Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark- The Lancet Gastroenterology & Hepatology https://t.co/O
RT @Carlosguillenas: Parece que terminamos el año con una buena noticia para los pacientes usuarios de aTNF. https://t.co/QJUstYLtdA @ConAr…
Use of anti-TNFα therapy was not associated with recurrent or new primary cancer development in patients with previous cancer. Timing of anti-TNFα therapy after an initial cancer diagnosis did not influence recurrent or new primary cancer development. http
Timing of anti-TNFα therapy after an initial cancer diagnosis did not influence recurrent or new primary cancer development
Parece que terminamos el año con una buena noticia para los pacientes usuarios de aTNF. https://t.co/QJUstYLtdA @ConArtritis @accionpsoriasis
RT @EricFMorand: wow this is a big one - safety (re cancer risk) of anti-TNF across inflammatory disease https://t.co/d1e4ky0Xb3
RT @WindermanMd: 👍🏻 Reassuring news Use of anti-TNFα therapy in IBD pts with h/o previous cancer ➡️ 🚫 a/w recurrence or new primary cance…
RT @LancetGastroHep: New Online: Use of anti-TNFα therapy for #inflammatoryboweldisease, #rheumatoidarthritis, or #psoriasis is not associa…
RT @LancetGastroHep: New Online: Use of anti-TNFα therapy for #inflammatoryboweldisease, #rheumatoidarthritis, or #psoriasis is not associa…
RT @LancetGastroHep: New Online: Use of anti-TNFα therapy for #inflammatoryboweldisease, #rheumatoidarthritis, or #psoriasis is not associa…